KalVista Pharmaceuticals (KALV) Operating Leases (2019 - 2025)

KalVista Pharmaceuticals (KALV) has 7 years of Operating Leases data on file, last reported at $4.0 million in Q3 2025.

• For the quarter ending Q3 2025, Operating Leases fell 19.43% year-over-year to $4.0 million; the trailing twelve-month figure through Jul 2025 stood at $4.0 million (down 19.43% YoY), and the FY2025 full-year result was $4.3 million, down 28.01% from the prior year.
• Operating Leases declined to $4.0 million in Q3 2025, from $4.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $8.0 million in Q3 2022 to a low of $1.1 million in Q1 2021.
• A 5-year average of $5.9 million and a median of $6.3 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases jumped 567.81% in 2021 and sank 33.73% in 2024, its largest moves.
• Tracing KALV's Operating Leases over 5 years: stood at $6.2 million in 2021, then grew by 23.79% to $7.7 million in 2022, then declined by 15.04% to $6.5 million in 2023, then sank by 32.22% to $4.4 million in 2024, then declined by 9.42% to $4.0 million in 2025.
• Business Quant data shows KALV's Operating Leases at $4.0 million in Q3 2025, $4.3 million in Q2 2025, and $4.4 million in Q4 2024.